SONX (Sonendo) 3-Year EBITDA Growth Rate: 0.00% (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SONX Sonendo Inc SONX
47 GF Score
Price $1.00
View Full Analysis

What is Sonendo 3-Year EBITDA Growth Rate?

Sonendo SONX 47 3-Year EBITDA Growth Rate is 0.00% as of Dec. 2024. GuruFocus rates SONX with a GF Score™ of 47/100.

Sonendo's EBITDA per Share for the three months ended in Dec. 2024 was $-10.94.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Sonendo  (OTCPK:SONX) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Sonendo 3-Year EBITDA Growth Rate Related Terms

SONX vs DHAI, AFIB, ABT: 3-Year EBITDA Growth Rate Comparison

For the Medical Devices subindustry, Sonendo's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sonendo 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sonendo's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Sonendo's 3-Year EBITDA Growth Rate falls into.


SONX
47GF Score
Sonendo Inc SONX
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sonendo 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Sonendo (SONX) has a 3-Year EBITDA Growth Rate of 0.00% as of Dec. 2024. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sonendo and its competitors.
Is Sonendo's 3-Year EBITDA Growth Rate too high?
Sonendo's current 3-Year EBITDA Growth Rate is 0.00%. Overall, Sonendo has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Sonendo's 3-Year EBITDA Growth Rate compare to DHAI and AFIB?
Sonendo's 3-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Medical Devices & Instruments industry. The industry median 3-Year EBITDA Growth Rate is 8.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sonendo and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sonendo's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonendo stock overvalued right now?
Sonendo (SONX) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. Sonendo's overall GF Score™ is 47/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Sonendo (SONX), the current 3-Year EBITDA Growth Rate is 0.00% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sonendo Business Description

Address 26061 Merit Circle, Suite 102, Laguna Hills, CA, USA, 92653
Sonendo Inc is a commercial-stage medical technology company focused on saving teeth from tooth decay, the prevalent chronic disease globally. It has developed the GentleWave System, a technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The company operates in two business segments, Product segment which derives key revenue, and Software. Product segment includes sales of the Company's GentleWave System console and related accessories and instruments. Software segment includes sales of the company's traditional software licenses for practice management software to enable an integrated digital office for endodontists.
47GF Score

Get the complete analysis for SONX

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.00
Price